XML 49 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900
Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)
shares in Thousands
1 Months Ended 12 Months Ended
Nov. 06, 2013
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Mar. 09, 2011
Currency Hedge Agreement [Member]            
Collateral Already Posted, Aggregate Fair Value     $ 0 $ 0    
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]            
Derivative, Loss on Derivative     564,000      
Derivative, Gain on Derivative     $ 1,654,000 5,487,000 $ 5,294,000  
JPR Royalty Sub LLC [Member]            
Revenue Recognition Royalty and Milestone Revenue Recognized           $ 30,000,000
Maximum [Member]            
Maturity of Investments     3 years      
Maturity Period of High Quality Marketable Securities     3 years      
Average Maturity Period of High Quality Marketable Securities     1 year 180 days      
Maturity Period of Short Term Investment     1 year      
Average Maturity for Portfolio Investments     1 year 180 days      
Minimum [Member]            
Maturity Period of Short Term Investment     90 days      
Long-term Investment Maturity, Minimum     1 year      
Certificates of Deposit [Member]            
Restricted Cash and Cash Equivalents, Current     $ 150,000      
Royalty Receivable [Member]            
Restricted Cash and Cash Equivalents, Current     59,000      
Collateral for Credit [Member]            
Restricted Cash and Cash Equivalents     $ 1,403,000      
Computer Equipment [Member]            
Property, Plant and Equipment, Useful Life     3 years      
Laboratory Equipment, Office Equipment and Software [Member]            
Property, Plant and Equipment, Useful Life     5 years      
Furniture and Fixtures [Member]            
Property, Plant and Equipment, Useful Life     7 years      
Building [Member]            
Property, Plant and Equipment, Useful Life     10 years      
Agreement [Member] | CSL [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]            
Proceeds from License Fees Received   $ 7,000,000        
Agreement [Member] | CSL [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]            
Deferred Revenue, Additions   3,740,000        
Agreement [Member] | CSL [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]            
Deferred Revenue, Additions   1,223,000        
Agreement [Member] | CSL [Member] | RAPIVABMember            
Proceeds from License Fees Received   33,740,000        
Revenues   21,777,000        
Milestone Payment Maximum   $ 12,000,000        
RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]            
Concentration Risk, Percentage     90.00%      
PhaRMA Notes Member]            
Interest Expense     $ 5,200,000 4,998,000 4,778,000  
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     13,000 0    
Amortization of Financing Costs     439,000 439,000 439,000  
Investments and Cash     100,858,000      
Securities Offered $ 10,000,000          
Restricted Cash and Cash Equivalents, Current     1,612,000 150,000    
Revenues     48,257,000 13,608,000 17,331,000  
Advertising Expense     103,000 290,000    
Interest Expense     $ 5,200,000 $ 4,998,000 $ 4,778,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     3,524 3,991 1,430